The effect of fellow eye visual acuity on visual acuity of study eyes receiving ranibizumab for age-related macular degeneration

Retina

Volumn 32, Issue 7, 2012, Pages 1243-1249

  Zweifel, Sandrine A ^a   Saroj, Namrata ^b   Shapiro, Howard ^b   Bailey Freund, K ^c  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b GENENTECH INC   (United States)

^c VITREOUS RETINA MACULA CONSULTANTS OF NEW YORK   (United States)

Author keywords

ANCHOR trial; anti vascular endothelial growth factor; eccentric fixation; intravitreal injections; MARINA trial; neovascular AMD

Indexed keywords

RANIBIZUMAB;

AGED; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHOTODYNAMIC THERAPY; PREDICTOR VARIABLE; RETINA MACULA AGE RELATED DEGENERATION; RETROSPECTIVE STUDY; TREATMENT OUTCOME; VISUAL ACUITY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; FUNCTIONAL LATERALITY; HUMANS; INTRAVITREAL INJECTIONS; MALE; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84862846937     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0b013e3182469064     Document Type: Article

References (24)

1. Klein R, Cruickshanks KJ, Nash SD, et al. The prevalence of age-related macular degeneration and associated risk factors. Arch Ophthalmol 2010;128:750-758.
2. Rosenfeld PJ, Brown DM, Heier JS, et al. MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-1431. (Pubitemid 44511557)
3. Brown DM, Kaiser PK, Michels M, et al. ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-1444. (Pubitemid 44511558)
4. Brown DM, Michels M, Kaiser PK et al. ANCHOR Study Group. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 2009;116:57-65.e5.
5. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intra-vitreal ranibizumab (Lucentis®) for neovascular age-related macular degeneration. Am J Ophthalmol 2007;143:566-583.
6. Sayanagi K, Sharma S, Kaiser PK Photoreceptor status after antivascular endothelial growth factor therapy in exudative age-related macular degeneration. Br J Ophthalmol 2009;93:622-626.
7. Engelbert M, Zweifel SA, Freund KB. "Treat and extend" dosing of intravitreal antivascular endothelial growth factor therapy for type 3 neovascularization/retinal angiomatous proliferation. Retina 2009;29:1424-1431.
8. Engelbert M, Zweifel SA, Freund KB. Long-term follow-up for type 1 (subretinal pigment epithelium) neovascularization using a modified "treat and extend" dosing regimen of intravitreal antivascular endothelial growth factor therapy. Retina 2010;30:1368-1375.
9. Freund KB, Zweifel SA, Engelbert M. Do We Need a New Classification for Choroidal Neovascularization in Age-Related Macular Degeneration? Retina 2010;30:1333-1349.
10. Heimes B, Lommatzsch A, Zeimer M, et al. Anti-VEGF therapy of exudative AMD : Prognostic factors for therapy success [in German]. Ophthalmologe 2011;108:124-131.
11. Lee SJ, Koh HJ. Effects of Vitreomacular Adhesion on Anti-Vascular Endothelial Growth Factor Treatment for Exudative Age-Related Macular Degeneration. Ophthalmology 2011; 118:101-110.
12. Tsuchihashi T, Mori K, Horie-Inoue K, et al. Complement Factor H and High-Temperature Requirement A-1 Genotypes and Treatment Response of Age-related Macular Degeneration. Ophthalmology 2011;118:93-100.
13. Stangos AN, Gandhi JS, Nair-Sahni J, et al. Polypoidal Cho-roidal Vasculopathy Masquerading as Neovascular Age-Related Macular Degeneration Refractory to Ranibizumab. Am J Ophthalmol 2010;150:666-673.
14. Cho M, Barbazetto IA, Freund KB. Refractory neovascular age-related macular degeneration secondary to polypoidal cho-roidal vasculopathy. Am J Ophthalmol 2009;148:170-178.e1.
15. Kaiser PK, Brown DM, Zhang K, et al. Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results. Am J Ophthalmol 2007;144:850-857.
16. Goverdhan SV, Hannan S, Newsom RB, et al. An analysis of the CFH Y402H genotype in AMD patients and controls from the UK, and response to PDT treatment. Eye (Lond) 2008;22: 849-854. (Pubitemid 351850525)
17. Heimes B, Lommatzsch A, Zeimer M, et al. Foveal RPE autofluorescence as a prognostic factor for anti-VEGF therapy in exudative AMD. Graefes Arch Clin Exp Ophthalmol 2008; 246:1229-1234.
18. Doris N, Hart PM, Chakravarthy U, et al. Relation between macular morphology and visual function in patients with cho-roidal neovascularisation of age related macular degeneration. Br J Ophthalmol 2001;85:184-188. (Pubitemid 32146758)
19. Singerman LJ, Wong B, Ai E, Smith S. Spontaneous visual improvement in the first affected eye of patients with bilateral disciform scars. Retina 1985;5:135-143. (Pubitemid 16214703)
20. Behrendt C. Visual acuity and its decrease in classic neovas-cular age-related macular degeneration. Ophthalmic Epidemiol 2004;11:359-367. (Pubitemid 40095930)
21. Sunness JS, Applegate CA, Gonzalez-Baron J. Improvement of visual acuity over time in patients with bilateral geographic atrophy from age-related macular degeneration. Retina 2000; 20:162-169. (Pubitemid 30395711)
22. Ishiko S, van de Velde F, Yoshida A. Paradoxical improvement of visual acuity in macular disease. Curr Eye Res 2010; 35:651-656.
23. Zweifel SA, Imamura Y, Spaide TC, et al. Prevalence and significance of subretinal drusenoid deposits (reticular pseudodrusen) in age-related macular degeneration. Ophthalmology 2010;117:1775-1781.
24. Pauleikhoff D, Radermacher M, Spital G, et al. Visual prognosis of second eyes in patients with unilateral late exudative age-related macular degeneration. Graefes Arch Clin Exp Oph-thalmol 2002;240:539-542. (Pubitemid 36097081)